PanXome utilizes ligand homology modeling to identify potential ligands for target proteins for which there are no known small molecule binders, nor known structures of the protein. Ligand homology modeling employs ligands from homologous template proteins for which structures have been determined and ligands are known. We extend this methodology to protein binding pockets for which there are no homologous holo templates. This is done by exploiting the fact that there are a limited number of distinct small molecule binding pockets across all proteins. We find a homologous binding pocket and use this as a template for virtual ligand screening.

 

CONVENTIONAL
EXPERIMENTAL STRUCTURE APPROACH

Screen Shot 2017-07-31 at 11.59.39 AM copy.png

PANXOME
PREDICTED STRUCTURE APPROACH

Screen Shot 2017-07-32 at 11.59.39 AM copy.png
  • Conventional approach requires experimentally solving a high resolution protein crystal structure.

  • Experimentally solved structures or close homology models are only available for about 25% of the human exome.

  • Conventional approach is computationally inefficient and ineffective on predicted structures. 

  • Even if structures were available, using this approach for side effect predictions is impractical due to computational inefficiency.

  • PanXome utilizes homology and ligand similarity which is very effective on both experimental structures and predicted structures. 

  • PanXome's method is effective on 86% of the human exome.

  • PanXome's methodology is extremely computationally efficient, utilizing both high resolution and low resolution predictions.

  • Because of computational efficiency and span of coverage, PanXome's approach is very effective at side effect predictions.

 

PANXOME PLATFORM

Screen Shot 2017-08-02 at 2.38.40 PM.png

 



The diagram to the left is a high-level depiction of how the PanXome platform operates. Using protein homology and ligand similarity, we determined which drugs bind to which proteins. The platform then associates target proteins with side effects (and other disease target proteins). We also use “Omic” data sources to further associate proteins with diseases.

 


IN VIVO/IN VITRO EXPERIMENTAL VALIDATION
 

In addition to proprietary/confidential work done for customers, the platform has been extensively tested and validated in Vivo/in Vitro and documented through peer-reviewed publications in major journals.  Through this testing, PanXome has identified drugs potentially effective for:

In Vivo:

  • Colon Carcinoma

  • MRSA

  • e. Coli

  • Anti-aging

In Vitro:

  • Glaucoma


PAPERS AND PUBLICATIONS

 

TARGET DISCOVERY & ID

LEAD IDENTIFICATION

DRUG DE-RISKING

DRUG REPURPOSING